# Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

> **NCT01265576** · PHASE2 · UNKNOWN · sponsor: **Vicus Therapeutics** · enrollment: 20 (actual)

## Conditions studied

- HCC

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** VT-122 (propranolol plus etodolac)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01265576
- **Lead sponsor:** Vicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-12
- **Primary completion:** 2014-02
- **Final completion:** 2016-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01265576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01265576, "Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01265576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*